Humoral and cell-mediated adaptive immune responses are required for protection against Burkholderia pseudomallei challenge and bacterial clearance postinfection.
about
Development of Burkholderia mallei and pseudomallei vaccinesMelioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposesFrom crystal structure to in silico epitope discovery in the Burkholderia pseudomallei flagellar hook-associated protein FlgKDevelopment of a humanized HLA-A2.1/DP4 transgenic mouse model and the use of this model to map HLA-DP4-restricted epitopes of HBV envelope proteinRecombinant Salmonella Expressing Burkholderia mallei LPS O Antigen Provides Protection in a Murine Model of Melioidosis and Glanders.Host immunity in the protective response to vaccination with heat-killed Burkholderia mallei.Immunogenic Burkholderia pseudomallei outer membrane proteins as potential candidate vaccine targets.A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis.Protection against experimental melioidosis following immunisation with a lipopolysaccharide-protein conjugate.Immunospecific responses to bacterial elongation factor Tu during Burkholderia infection and immunization.Burkholderia pseudomallei capsular polysaccharide conjugates provide protection against acute melioidosisInhibitory effects of progesterone differ in dendritic cells from female and male rodents.Human immune responses to Burkholderia pseudomallei characterized by protein microarray analysis.Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis.Development of vaccines against burkholderia pseudomallei.A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection.Specific activation of dendritic cells enhances clearance of Bacillus anthracis following infection.Sequence- and Structure-Based Immunoreactive Epitope Discovery for Burkholderia pseudomallei FlagellinRapid and Sensitive Multiplex Detection of Burkholderia pseudomallei-Specific Antibodies in Melioidosis Patients Based on a Protein Microarray Approach.Immunogenic recombinant Burkholderia pseudomallei MprA serine protease elicits protective immunity in miceBurkholderia vaccines: are we moving forward?Burkholderia pseudomallei infection of T cells leads to T-cell costimulation partially provided by flagellin.An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.Generation of human MHC (HLA-A11/DR1) transgenic mice for vaccine evaluation.Predictive models and correlates of protection for testing biodefence vaccines.Melioidosis and glanders modulation of the innate immune system: barriers to current and future vaccine approaches.Migration of dendritic cells facilitates systemic dissemination of Burkholderia pseudomallei.A monoclonal antibody to Histoplasma capsulatum alters the intracellular fate of the fungus in murine macrophages.Recent Advances in Burkholderia mallei and B. pseudomallei Research.Anti-Cancer Drug HMBA Acts as an Adjuvant during Intracellular Bacterial Infections by Inducing Type I IFN through STING.Pathogenesis of percutaneous infection of goats with Burkholderia pseudomallei: clinical, pathologic, and immunological responses in chronic melioidosis.The fraction 1 and V protein antigens of Yersinia pestis activate dendritic cells to induce primary T cell responses.Progesterone regulation of uterine dendritic cell function in rodents is dependent on the stage of estrous cycle.A Burkholderia pseudomallei Outer Membrane Vesicle Vaccine Provides Cross Protection against Inhalational Glanders in Mice and Non-Human Primates.Melioidosis: where do we stand in the development of an effective vaccine?
P2860
Q26861271-B02C7813-A637-44B2-9126-05647618648DQ27305733-E7CDA6BE-CAC9-4F3F-ACDF-61B6C12F9B88Q27697853-E78F1CDA-773C-4515-89F9-D96968F69C49Q28731516-23360864-A616-403B-9F63-D59A56AF3589Q30279061-1E7E3652-46C2-4607-9839-C6B50550AB20Q33372589-C5786985-B7EF-4C3A-A6E2-AFC569DCA288Q33490609-92182DD5-6991-4C6B-A978-3FDCE366DCC2Q33601907-DD84B1E7-B7C8-4B5A-AECC-763CCBA979FCQ33661479-2215E735-35BD-4271-A267-5A183AD0721FQ33778331-619D84F6-5706-40E0-9193-3C8225C7ABF5Q34058969-3D1A418D-471D-44AF-8DE7-40723321E359Q34137092-B51BA046-8230-4879-A3DB-0D0C0E170750Q34743375-568ABB30-E7A1-44D5-A143-81B84E90471FQ35129390-46D711F0-821E-4E7F-9400-18C6520DB462Q35234118-37E38D84-77F4-4C70-8BF8-EF5D96996BDFQ35375333-53B2921B-F5E0-4FC8-8684-B0AC1EA1A3F6Q35403794-EF8D5996-2981-4C86-A115-604F4DACED8DQ35723661-AC525F27-FCC9-470D-87DD-5CF1F50C6751Q36079942-CF10AD11-0546-4BA8-B2C9-575E359ED60EQ36159605-E383AA6C-A9EE-4B5C-B017-CCE7CA32763CQ36587103-566181B8-F7AE-445A-8FB0-E1AA545A5B73Q36710590-D53CCA86-EE64-4A45-A233-4998CBEC68A8Q37120769-2E2EB1D6-54F6-40CD-931C-B17FBB169467Q37135201-3475EECD-449E-449E-8E78-7007D112B727Q37745002-C7A64A50-00EF-4A80-8CFA-6CA93B1F40D4Q38890754-47669414-9063-4323-BFCE-BF8D8A46CA3DQ39595676-791A7BC5-69D7-40DA-889B-BB35AEE05C08Q39756786-1E8F2F68-0DC8-449D-BE8A-9E5780492FEAQ39970602-9B3DEE30-2719-420C-87D3-FFD7F31B7EDCQ40085222-1ED8FD0D-9C78-4928-8C66-8644E37D2E2AQ40216703-5C6624B2-BCEB-4E7D-8A79-FC307D3A1A5BQ41447968-4A5EEB86-3554-41F3-9F22-DCDBA3833A8BQ43053417-47309F39-1CB3-4B2B-A87E-CCC86037916AQ46242885-C1D8E2E8-9EA4-4629-905E-554D95B6578DQ48144660-392E7A5A-7EF1-4835-ADE8-6E57D7EDAD18
P2860
Humoral and cell-mediated adaptive immune responses are required for protection against Burkholderia pseudomallei challenge and bacterial clearance postinfection.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Humoral and cell-mediated adap ...... erial clearance postinfection.
@ast
Humoral and cell-mediated adap ...... erial clearance postinfection.
@en
Humoral and cell-mediated adap ...... erial clearance postinfection.
@nl
type
label
Humoral and cell-mediated adap ...... erial clearance postinfection.
@ast
Humoral and cell-mediated adap ...... erial clearance postinfection.
@en
Humoral and cell-mediated adap ...... erial clearance postinfection.
@nl
prefLabel
Humoral and cell-mediated adap ...... erial clearance postinfection.
@ast
Humoral and cell-mediated adap ...... erial clearance postinfection.
@en
Humoral and cell-mediated adap ...... erial clearance postinfection.
@nl
P2093
P2860
P1476
Humoral and cell-mediated adap ...... terial clearance postinfection
@en
P2093
E Diane Williamson
Margaret Morton
Stephen J Elvin
P2860
P304
P356
10.1128/IAI.73.9.5945-5951.2005
P407
P577
2005-09-01T00:00:00Z